Liberty Capital Management Inc. lessened its stake in shares of CVS Health Corp (NYSE:CVS) by 6.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 32,525 shares of the pharmacy operator’s stock after selling 2,360 shares during the quarter. Liberty Capital Management Inc.’s holdings in CVS Health were worth $2,486,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Jackson Grant Investment Advisers Inc. grew its holdings in shares of CVS Health by 0.6% during the second quarter. Jackson Grant Investment Advisers Inc. now owns 2,881 shares of the pharmacy operator’s stock worth $232,000 after purchasing an additional 18 shares in the last quarter. Elefante Mark B grew its holdings in shares of CVS Health by 0.7% during the second quarter. Elefante Mark B now owns 6,400 shares of the pharmacy operator’s stock worth $515,000 after purchasing an additional 45 shares in the last quarter. Traynor Capital Management Inc. grew its holdings in shares of CVS Health by 1.3% during the second quarter. Traynor Capital Management Inc. now owns 3,676 shares of the pharmacy operator’s stock worth $290,000 after purchasing an additional 48 shares in the last quarter. Sequoia Financial Advisors LLC grew its holdings in shares of CVS Health by 0.8% during the second quarter. Sequoia Financial Advisors LLC now owns 6,406 shares of the pharmacy operator’s stock worth $515,000 after purchasing an additional 53 shares in the last quarter. Finally, Brookstone Capital Management grew its holdings in shares of CVS Health by 1.8% during the second quarter. Brookstone Capital Management now owns 3,153 shares of the pharmacy operator’s stock worth $254,000 after purchasing an additional 55 shares in the last quarter. 81.63% of the stock is owned by institutional investors and hedge funds.

Shares of CVS Health Corp (NYSE:CVS) opened at $73.68 on Wednesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.55. CVS Health Corp has a 12-month low of $66.45 and a 12-month high of $84.72. The firm has a market capitalization of $74,640.00, a P/E ratio of 15.22, a price-to-earnings-growth ratio of 1.38 and a beta of 0.89.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.49 by $0.01. CVS Health had a return on equity of 14.90% and a net margin of 2.78%. The firm had revenue of $46.18 billion during the quarter, compared to the consensus estimate of $46.17 billion. During the same quarter in the previous year, the company posted $1.64 earnings per share. The business’s revenue was up 3.5% on a year-over-year basis. equities research analysts forecast that CVS Health Corp will post 5.9 EPS for the current fiscal year.

CVS has been the subject of several recent analyst reports. Oppenheimer reissued a “buy” rating and set a $95.00 price objective on shares of CVS Health in a report on Monday, October 9th. SunTrust Banks set a $85.00 target price on CVS Health and gave the stock a “buy” rating in a research note on Thursday, October 12th. Mizuho set a $90.00 target price on CVS Health and gave the stock a “buy” rating in a research note on Tuesday, October 24th. Cowen set a $86.00 target price on CVS Health and gave the stock a “buy” rating in a research note on Sunday, October 29th. Finally, Needham & Company LLC raised CVS Health from a “hold” rating to a “buy” rating and upped their target price for the stock from $69.02 to $79.00 in a research note on Friday, November 10th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $86.35.

In other CVS Health news, EVP Lisa Bisaccia sold 29,445 shares of the business’s stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $75.00, for a total value of $2,208,375.00. Following the completion of the sale, the executive vice president now owns 15,556 shares in the company, valued at $1,166,700. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Thomas M. Moriarty sold 20,547 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $81.17, for a total value of $1,667,799.99. Following the completion of the sale, the executive vice president now owns 43,178 shares of the company’s stock, valued at approximately $3,504,758.26. The disclosure for this sale can be found here. Insiders own 0.61% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://theolympiareport.com/2017/12/27/cvs-health-corp-cvs-holdings-trimmed-by-liberty-capital-management-inc.html.

About CVS Health

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with Analyst Ratings Network's FREE daily email newsletter.